BIOAVAILABILITY AND CARDIOVASCULAR SAFETY OF DEXATRIM (PHENYLPROPANOLAMINE HYDROCHLORIDE) FROM A CONTROLLED-RELEASE CAPLET

被引:4
作者
SHARGEL, L
SILVERMAN, HI
COHEN, P
BRISSON, J
DENNIS, S
机构
[1] THOMPSON MED CO INC,NEW YORK,NY 10022
[2] HAZLETON LABS AMERICA INC,MADISON,WI 53704
关键词
Bioavailability; Biopharmaceutics; Blood pressure; Controlled release; Pharmacokinetics; Phenylpropanolamine hydrochloride;
D O I
10.1002/bdd.2510110703
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The bioavailability and pharmacokinetics of phenylpropanolamine hydrochloride (PPA HCl) from a Dexatrim® controlled‐release (CR) caplet and solution was studied. Each subject (n = 12) received either a 75 mg PPA HCl CR caplet once daily or a 25 mg PPA HCl solution given three times a day. All subjects received the medication for 4 consecutive days. On Day 1, the mean ± SEM, AUC, tmax, and Cmax values were 1651 ± 127 ng x h ml−1, 4·5 ± 0·26 h and 143 ± 13·5 ng ml−1, respectively, for the CR caplet and 1716 ± 90·3ng × h ml−1, 1·25 ± 0·08 h and 126 ± 5·8 ng ml−1 for the solution, respectively. At steady state (Day 4), the mean ± SEM, AUC, tmax, and Cmax values were 1832 ± 101 ng x h ml−1, 4·17 ± 0·17 h and 151 ± 6·5 ng ml−1, respectively, for the CR caplet and 2014 ± 116 ng x h ml−1, 1·33 ± 0·09 h and 143 ± 8·7 ng ml−1, respectively, for the solution. The data from Day 1 were fitted to an oral one compartment model with a first order absorption rate constant, kA, first order elimination rate constant, k and lag time. The mean ± SEM, kA, elimination half‐life and lag time for PPA HCl from the CR caplet were 0·488 ± 0·182 ng h ml−1, 5·84 ± 1·66 h and 0·394 ± 0·224 h, respectively. The mean ± SEM, kA, elimination half‐life and lag time for PPA HCl from the solution were 2·87 ± 1·51 ng x h ml−1, 3·73 ± 1·21 h, and 0·325 ± 0·101 h. respectively. The smaller apparent kA and longer elimination half‐life for PPA HCl from the CR caplet is due to the slow release of PPA HCl, thereby slowing its absorption producing sustained plasma drug concentrations. Blood pressures (supine and sitting) and heart rates measured at the time of blood sampling after the administration of the PPA HCl dosage forms demonstrated no clinically significant relationship between cardiovascular response and PPA HCl plasma concentration. These data demonstrate the bioavailability and pharmacokinetics of PPA HCl from a CR caplet and an immediate release solution. Copyright © 1990 John Wiley & Sons, Ltd.
引用
收藏
页码:569 / 583
页数:15
相关论文
共 22 条
  • [1] AXELROD J, 1973, J PHARM EXPT THER, V109, P62
  • [2] BARRETT WE, 1981, CURR THER RES CLIN E, V30, P640
  • [3] DIXON WJ, 1969, INTRO STATISTICAL AN
  • [4] PHARMACOKINETICS OF PHENYLPROPANOLAMINE IN HUMANS AFTER A SINGLE-DOSE STUDY
    DOWSE, R
    HAIGH, JM
    KANFER, I
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1987, 39 (1-2) : 141 - 148
  • [5] THE EFFECT OF PHENYLPROPANOLAMINE ON AMBULATORY BLOOD-PRESSURE
    GOODMAN, RP
    WRIGHT, JT
    BARLASCINI, CO
    MCKENNEY, JM
    LAMBERT, CM
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1986, 40 (02) : 144 - 147
  • [6] EVALUATION OF A SUSTAINED RELEASE FORM OF PHENYLPROPANOLAMINE HYDROCHLORIDE BY URINARY EXCRETION STUDIES
    HEIMLICH, KR
    OBRIEN, PD
    MACDONNELL, DR
    FLANAGAN, TL
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 1961, 50 (03) : 232 - &
  • [7] PHENYLPROPANOLAMINE PHARMACOKINETICS IN DOGS AFTER INTRAVENOUS, ORAL, AND ORAL CONTROLLED-RELEASE DOSES
    HUSSAIN, MA
    AUNGST, BJ
    LAM, G
    SHEFTER, E
    [J]. BIOPHARMACEUTICS & DRUG DISPOSITION, 1987, 8 (05) : 497 - 505
  • [8] THE EFFECTS OF PHENYLPROPANOLAMINE ON HUMAN SYMPATHETIC NERVOUS-SYSTEM FUNCTION
    LAKE, CR
    CHERNOW, B
    ZALOGA, G
    LABOW, J
    QUIRK, R
    HEDGES, SM
    [J]. NEUROPSYCHOPHARMACOLOGY, 1988, 1 (02) : 163 - 168
  • [9] PHENYLPROPANOLAMINE AND BLOOD-PRESSURE
    LASAGNA, L
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1985, 253 (17): : 2491 - 2492
  • [10] PHENYLPROPANOLAMINE - EFFECTS ON SUBJECTIVE AND CARDIOVASCULAR VARIABLES AT RECOMMENDED OVER-THE-COUNTER DOSE LEVELS
    LIEBSON, I
    BIGELOW, G
    GRIFFITHS, RR
    FUNDERBURK, FR
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 27 (09) : 685 - 693